Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy.

Item

http://www.wikidata.org/entity/Q36606643

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Expanded risk groups help dete ...... androgen deprivation therapy.

@ast

Expanded risk groups help dete ...... androgen deprivation therapy.

@en

type

Item

label

Expanded risk groups help dete ...... androgen deprivation therapy.

@ast

Expanded risk groups help dete ...... androgen deprivation therapy.

@en

prefLabel

Expanded risk groups help dete ...... androgen deprivation therapy.

@ast

Expanded risk groups help dete ...... androgen deprivation therapy.

@en

P1476

Expanded risk groups help dete ...... androgen deprivation therapy.

@en

P2093

BCCA Prostate Outcomes Unit

http://www.w3.org/2001/XMLSchema#string

Matthew Beasley

http://www.w3.org/2001/XMLSchema#string

Scott G Williams

http://www.w3.org/2001/XMLSchema#string

Tom Pickles

http://www.w3.org/2001/XMLSchema#string

P2860

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.

An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk.

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.

Complications of androgen deprivation therapy for prostate cancer.

Androgen deprivation therapy for prostate cancer.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

P2888

1748-717x-3-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1748-717X-3-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5429715

http://www.w3.org/2001/XMLSchema#string

P6179

1052730739

http://www.w3.org/2001/XMLSchema#string

P698

18423030

http://www.w3.org/2001/XMLSchema#string

P932

2358899

http://www.w3.org/2001/XMLSchema#string